Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Chugai Pharmaceutical has recieved Ministry of Health, Labour and Welfare approval to manufacture and market a long-acting erythropoiesis stimulating agent (ESA) branded as Mircera Injection Syringe is available as 25mg, 50mg, 75mg, 100mg, 150mg, 200mg, and 250mg for the treatment of renal anemia.
Subscribe to our email newsletter
Mircera Injection Syringe uses epoetin beta (genetical recombination) which is chemically combined with a single molecule of linear methoxy polyethylene glycol (PEG).
It has a longer serum half-life than other available ESAs such as Epogin Injection, enabling it to maintain hemoglobin levels targeted under the guideline for treatment of renal anemia with once-every-four-week intravenous or subcutaneous dosing.
A clinical study of the drug has confirmed that the drug brings about stable anemia improvement and maintenance effects against renal anemia seen in patients who undergo hemodialysis or peritoneal dialysis, as well as those patients who are treated for chronic kidney disease at a prior stage of entering dialysis treatment.
Mircera Injection Syringe is expected to treat chronic kidney disease, offering improved convenience for the patients such as fewer hospital visits and enhanced quality of life (QOL), and also reducing the burden for healthcare professionals.